Ionis Announces Clinical Progress With Donidalorsen, Its Late-stage Investigational Prophylactic Therapy For Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals announced positive topline two-year open-label extension results for its late-stage investigational prophylactic therapy, Donidalorsen, for Hereditary Angioedema. The results showed a sustained mean reduction in HAE attack rates of 96% across dosing groups.
June 01, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ionis Pharmaceuticals' Donidalorsen shows promising results in reducing HAE attack rates by 96%, potentially boosting the company's stock price.
The positive results from the two-year open-label extension study of Donidalorsen indicate that the therapy is effective in reducing HAE attack rates. This could lead to increased investor confidence in Ionis Pharmaceuticals and potentially boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100